Phase II Trial of Apixaban in Japanese Patients with Cancer-Associated Venous Thromboembolism
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms J-CAV study
- 29 Sep 2019 Status changed from recruiting to discontinued.
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.
- 05 Dec 2017 Planned initiation date changed from 9 Jan 2018 to 1 Feb 2018.